¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º [S6u:;7  
E,i^rAm  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ e@3SF  
M;A_'h?Z  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) f) sy-o!  
f&-`+V}U  
1. ICAM-1 1}VaBsEV  
F^l1WX6  
2. interleukin 12(IL-12) >a"J);p  
EjP;P}_i K  
3. tumor infiltrating lymphocyte [6VB&   
TXImmkC  
4. TCR/CD3 complex \M`qaFan5^  
zTng]Mvx  
5. hematopoietin receptor family [ycX)iM  
7Kw'Y8  
6. individual idiotype(IdI) L;V 8c  
Q<sqlh!h  
7. integrin }aWy#Oe  
[8QK @5[  
8. colony-stimulatory factor (CSF) p]aEC+q  
 'z} t= ?  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© $ N?8[  
"#C2+S KM1  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? cSt)Na~C  
<+QdBp'd;  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ TgkVd]4%  
k9k39`t  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷ÓᣠY j oe|  
?L<B]!9HZt  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ tpWGmj fo>  
aUw-P{zp%  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) ,YD7p= PY  
2^r~->  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ 2cCiHEL#  
*OLqr/ yb  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) ]-gyXE1.r  
0pE >O 7  
3. immunoglobulin superfamily (IgSF) +byOThuE  
]dUG=dWO  
4. selectin K6DN>0sY  
TUfj\d,  
5. anti-idiotypic antibody (¦ÁId) hl1IG !  
sh  :$J[  
6. major histocompatibility complex(MHC) V,-we|"  
ed6@o4D/kf  
7. immunotolerance OjGI !  
AR [m+E  
8. biological reponse modifier(BRM) E0ED[d,  
}a;xs};X;  
9. immune reponse gene (Ir gene) ]$/oSa/  
*qzdt^[ xo  
10. reshaped antibody (or reconstituted antibody) 1G YZ1iA  
t'U=K>7  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© 3L&:  
)Q1>j 2 &  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ ^`cv6;)  
}5+^  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? .lcp5D[(  
5_(\Cd<#  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ CV0id&Nv  
Y D<3#Dr]  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? a&'9[9E1  
]^ R':YE  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ KZ5%q.  
':n`0+Eh  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? %Xh}{o$G  
}2]|*?1,  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ ~:Rbd9IB  
FtTq*[a  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ rn-bfzoDS  
~9]vd|  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? j- 9)Sijj{  
)^(gwE  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ jG1(Oe;#  
8c) eaDu  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: as@8L|i*  
?-j/X6(\(  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: f7*Qa!!2p]  
c+ZOC8R  
ÃâÒßѧ 20}HTV{v  
^;F/^ _  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 8-<F4^i_i  
uUjjAGZ  
1. CD8 2q[pOT'k  
+JI,6)Ry  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) J!om"h  
~Z5AImR|  
3. immunoglobulin fold(Ig fold) |pHlBzHj  
-1 dD~S$  
4. cadherin (Ca-dependent cell adhesion moleculers) Zv}F?4T~:  
N7s0Ua'-v  
5. idiotype-anti-idiotypic antibody immune network theory -;gQy[U  
LZ)g&A(j?  
6. HLA class II antigen Il&F C  
#;8)UNc)}  
7. complementarity-determining region (CDR) 4 Y=0>FlY0  
C rR/  
8. perforin(or pore-forming protein ,PFP) !BVCuuM>w  
Y-})/zFc  
9. high affinity IL-2 receptor uQ3sRJi  
pmP~1=3  
10. artificial active immunization '|gsmO  
&/[MWQ  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£©  B=*0  
<%.% q  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ(LsVd2AbR  
c9c]1XJ  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 zx<t{e7  
@MibKj>o  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ Zsapu1HoL\  
7Wef[N\x  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ ~ ?nn(Q-  
=xkaF)AW&v  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ PI L)(%X  
`=;}I@]zj)  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? w &YUb,{Y  
 #NyO'  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ Btznms'  
M>=@Z*u/+  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ j8Mt"B  
+h-% {  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ 9q0s  
a 7v^o`  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ .qe+"$K'n  
, l!>+@  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© +D @B eQu  
EyR/   
1. immunoglobulin gene rearrangement hwk] ;6[  
P_jav 0j7g  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) ^+%bh/2_W  
=M:Po0?0E  
3. flow cytometry(FCM) LTBH/[q5  
QpzdlB44l  
4. carrier effect 7Z +Fjy-B  
Msvs98LvW  
5. positive selection of T lymphocytes in thymus k]gPMhe  
Ax|'uvVAPT  
6. mouse TH1(Th1) and TH2(Th2) subsets **-rPonM[  
dVq9'{[3  
7. perforin (pore-forming protein ,PFP) q%bFR[p<*  
8S#&XS>o  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) V4u4{wU]  
g_PP 9S_?  
9. SH-2(src-homology region 2) vp&.  
D:K"J><@  
10. Ab2¦Â (internal image) 8T+o.w==  
bCTN^  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© *EO*Gg0d  
N?S;v&q+  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? .|DrXJ \c  
Y]~-S  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? lZkJ<*z#  
r1. zURY  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠ3GL?&(eU;  
O.Te"=^"F  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ r4K_Wp  
FwKY;^`!d  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠpi70^`@'B  
| Wj=%Ol%o  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) X16O9qsh  
s7jNRY V  
ÃâÒßѧרҵ£º st.{AEv@  
2u0B=0x  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ AL&<SxuP  
jL)Y'  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? ; X+.Ag  
uARkf'  
´«È¾²¡Ñ§×¨Òµ£º SY.koW  
0%|)=T3Slu  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ 4y4r;[@U  
k ^KpQ&n  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ D;48VK/Q  
T1?9E{bC8A  
Ïû»¯×¨Òµ£º @^# 9N!Fj]  
5yJ~ q  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ ^%6f%]_  
VgY6M_V  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? lA6{TH.x  
;Hp78!#,  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ 5,O:"3>c  
{~#01p5  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© @QYCoEU8J  
E+ XR[p  
1. Fas(CD95)/FasL XCgC^c'  
8A*tpMV?J  
2. common chain of cytokine receptor  "}[ ]R  
1b7?6CqV  
3 . TCR/CD3 complex =:TQ_>$Nc2  
U`{ M1@$  
4. negaive selection of thymocytes 6aAN8wO;b  
3EA_-?  
5. artificial active immune %X\Rfn0J"  
`sv]/8RN  
6. anti-idiotypic @P=n{-pIW  
xo-{N[r  
7. IgSF i!<(R$ Lo  
Jcp=<z*0  
8. Integrin -O@/S9]S)  
q#8z%/~k  
9. chemokine J3r':I}\  
5a&gdqg]  
10. B7/CD28 _JKz5hSl  
kWbY&]ZO  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© n@oSLo`k,`  
MGo`j:0  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ +xr;X 9  
#yCnM]cEn  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ 9q^7%b,  
1u* (=!   
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ \qJ^ n %  
OJ7y  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ AUaupNN  
JgldC[|7  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ (g tOYEqx  
(Q|Y*yI  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ J=#9eW  
$bk_%R}s  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© .n}k,da@(  
*MN("<A_  
1. B7/CD28 lF$$~ G  
;FjI!V  
2. Th1 subset w6l56 CB`  
DEenvS`,P  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© ;:Y/"5h  
,\PTn7_  
4. antibody affinity maturation ~A>-tn}O  
@N\ Ht'f  
5. AP-1 Sr6?^>A@t  
U9//m=_  
6. single chain variable fragment£¨ScFv£© 0h"uJco,  
p/jAr+XM  
7. NK cell receptor i,$n4  
*zDL 5 9  
8. Zinkernagel-Doherty phenomenon S%w67sGl4n  
aDX4}`u  
9. Ig fold <kWNx.eci  
%VgK::)r  
10. CD40/CD40L ;:ocU?  
D+Z,;XZ  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© boIFN;Aq"  
<``krPi  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ Qkg([q4  
)$E'2|Gm/  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ ltmD=-]G_  
d>1#|  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ M0uC0\' #P  
Z-z(SKL  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ [{rne2sA  
N+ei)-  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ ]4&B*]j  
coc :$Sr%  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ 1 s#GY<<  
SCD;(I~4  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ I$Fr8R$  
'5SO3/{b  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© U\",!S~<  
ju;Myi}a  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© f n\&%`U  
A/*h[N+2!  
1.Co-stimulators (or co-stimulating molecules) ^]?Yd)v  
Q02:qn?T  
2.NK-kB -*&C "%e  
3 p9LVa  
3.Immunoglobulin superfamily 3ocRq %%K  
2HJG p+H  
4.antigen-presenting cell (APC) uB uwE6  
FuZLE%gP  
5.death domain v D4<G{  
I45\xP4i  
6.CCR and CXCR p` LPO  
&T/}|3S  
7.Lectin (or mitogen) r$.v"Wh)  
;X2(G  
8.Clusters of differentiation, CD) /w*;|4~Bf  
) _O 6_  
9.B7 family 2wG4"  
* E3 c--  
10.Cytotoxic T lymphocyte, CTL) 6J%+pt[tu  
Z ]WA-Q6n  
11.IL-15 and IL-15 receptor (IL-15R) p~THliwd  
g?caE)  
12.MHC restriction xd`!z`X!,s  
~h*p A8^L  
13.Affinity-chromatography *!y.!v*  
\3@AC7  
14.Cyctosprin A, CsA Qvd$fY**  
6|D,`dk3U  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) s GP}>w-JZ  
~|~j01#  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© KGm"-W  
yxa~R z/  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 5Cs JghTw  
H19CVc\B  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ k(;c<Z{?1  
d>Z{TFY  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ ~=,|dGAa$  
'?~k`zK  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© [T.BK:  
 -'|pt,)  
ÃâÒßѧרҵ£º $bU|'}QR  
w^&TG3m1~  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ iM Xl}3  
kE".v|@  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ snBC +`-  
{O,Cc$_  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ jz$)*Kdi*  
"l&sDh%Lk<  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) x=qACoq  
%&"_=Lc  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) iw(\]tMt  
qb ^4G  
1. ADCC(antibody dependent cell-mediated cytotoxicity) X!n-nms  
9b !+kJD  
2. »·æß¾úËØ(cyclosporin) (iK0T.  
C<6IiF[>%  
3. KIR(killer cell inhibitory receptor) m4n J9<-  
1GW=QbO 6  
4. HLDA(human leucocyte differentiation antigen) t9PS5O ;  
doxQS ohS  
5. Interleukin 18(IL-18) }d)>pH  
]P ->xJ  
6. ÕûºÏËØ(integrin) (G"b)"Qum  
/ GJ"##<  
7. Fas/FasL oa`,|dA"  
;2}0Hr'|  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) '&3Sl?E  
5in6Y5ckj  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) P7 E}^y`e  
-2tX 15,  
10. Th1/Th2 {:Z#8dGe  
7 s5?^^  
11. »ùÒòÒßÃç(DNAÒßÃç) ix]3t^  
FWdSpaas Q  
12. chemokines and chemokine receptor r,MgIv(L  
#0L :h ?L  
13. ÃâÒßÄÍÊÜ u3 ?+Hu|*T  
Z[AJat@H  
14. ¹²´Ì¼¤·Ö×Ó J(M0t~RZ  
IVkKmO(qO  
15. ËÀÍö½á¹¹Óò(death domain) r em&F'x0V  
kzns:-a  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) UY{ Uo@k9x  
Fm,A<+l@u  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? .rG Rdb  
D/{Tl  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠtJ.LPgfZ  
xHykU;p@  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î 0'BR Sa<  
ui G7  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ RURO0`^  
5:CC\!&QBV  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå $NG}YOP)@  
Xj+1]KRN  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ +#1WOQfAD  
9eGM6qW\_  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) IOTHk+ w  
1.yw\ZC\  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ : [aUpX=  
z ;y2 2  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ Q`AJR$L  
:;{U2q+  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
5+2=? ÕýÈ·´ð°¸:7
°´"Ctrl+Enter"Ö±½ÓÌá½»